S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
NASDAQ:CLSD

Clearside Biomedical (CLSD) Stock Price, News & Analysis

$1.56
-0.15 (-8.77%)
(As of 03/18/2024 ET)
Today's Range
$1.49
$1.78
50-Day Range
$1.20
$2.02
52-Week Range
$0.65
$2.12
Volume
858,029 shs
Average Volume
347,576 shs
Market Capitalization
$116.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.75

Clearside Biomedical MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
204.5% Upside
$4.75 Price Target
Short Interest
Healthy
0.37% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.82mentions of Clearside Biomedical in the last 14 days
Based on 17 Articles This Week
Insider Trading
Acquiring Shares
$599,999 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.63) to ($0.58) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.86 out of 5 stars

Medical Sector

551st out of 947 stocks

Pharmaceutical Preparations Industry

256th out of 435 stocks

CLSD stock logo

About Clearside Biomedical Stock (NASDAQ:CLSD)

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

CLSD Stock Price History

CLSD Stock News Headlines

Central Bank Gold Heist In Progress
When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.
8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)
THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here:
Clearside Biomedical: Q4 Earnings Insights
Preview: Clearside Biomedical's Earnings
Clearside Biomedical, Inc. (CLSD)
CLSD Apr 2024 5.000 call
See More Headlines
Receive CLSD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
3/18/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CLSD
Employees
36
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.75
High Stock Price Target
$6.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+193.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-32,950,000.00
Net Margins
-394.91%
Pretax Margin
-394.91%

Debt

Sales & Book Value

Annual Sales
$8.23 million
Book Value
$0.18 per share

Miscellaneous

Free Float
67,398,000
Market Cap
$121.05 million
Optionable
Optionable
Beta
2.28
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. George M. Lasezkay J.D. (Age 72)
    Pharm.D., Pharma.D., President, CEO & Director
    Comp: $816.4k
  • Mr. Charles A. DeignanMr. Charles A. Deignan (Age 60)
    Chief Financial Officer
    Comp: $536.95k
  • Dr. Thomas A. Ciulla M.B.A. (Age 59)
    M.D., Chief Medical Advisor-Retina
    Comp: $597.21k
  • Ms. Jenny R. Kobin (Age 57)
    Head of Investor Relations
  • Mr. Rick McElheny
    Vice President of Corporate Development
  • Mr. Rafael V. Andino (Age 59)
    Senior Vice President of Engineering & Manufacturing
  • Ms. Susan L. Coultas Ph.D.
    Chief Clinical Officer
  • Mr. Leslie B. Zacks (Age 55)
    Secretary

CLSD Stock Analysis - Frequently Asked Questions

Should I buy or sell Clearside Biomedical stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLSD shares.
View CLSD analyst ratings
or view top-rated stocks.

What is Clearside Biomedical's stock price target for 2024?

4 brokers have issued 1 year price objectives for Clearside Biomedical's shares. Their CLSD share price targets range from $4.00 to $6.00. On average, they predict the company's stock price to reach $4.75 in the next twelve months. This suggests a possible upside of 204.5% from the stock's current price.
View analysts price targets for CLSD
or view top-rated stocks among Wall Street analysts.

How have CLSD shares performed in 2024?

Clearside Biomedical's stock was trading at $1.17 at the beginning of the year. Since then, CLSD shares have increased by 33.3% and is now trading at $1.56.
View the best growth stocks for 2024 here
.

Are investors shorting Clearside Biomedical?

Clearside Biomedical saw a increase in short interest in the month of February. As of February 29th, there was short interest totaling 275,400 shares, an increase of 70.1% from the February 14th total of 161,900 shares. Based on an average daily volume of 282,500 shares, the days-to-cover ratio is currently 1.0 days.
View Clearside Biomedical's Short Interest
.

When is Clearside Biomedical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CLSD earnings forecast
.

How were Clearside Biomedical's earnings last quarter?

Clearside Biomedical, Inc. (NASDAQ:CLSD) announced its quarterly earnings results on Monday, November, 13th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.01. The company had revenue of $0.86 million for the quarter, compared to analyst estimates of $0.22 million. Clearside Biomedical had a negative trailing twelve-month return on equity of 533.87% and a negative net margin of 394.91%. During the same quarter in the previous year, the firm posted ($0.13) earnings per share.

What other stocks do shareholders of Clearside Biomedical own?
When did Clearside Biomedical IPO?

(CLSD) raised $50 million in an initial public offering (IPO) on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

Who are Clearside Biomedical's major shareholders?

Clearside Biomedical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.42%), Vanguard Group Inc. (3.42%), Stifel Financial Corp (0.05%), Simplex Trading LLC (0.00%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bradford T Whitmore, Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, Nancy J Hutson, Richard T Burke and Thomas Ciulla.
View institutional ownership trends
.

How do I buy shares of Clearside Biomedical?

Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CLSD) was last updated on 3/18/2024 by MarketBeat.com Staff

From Our Partners